Massachusetts governor warns early-stage biotech firms of capital crunch ahead of election

Massachusetts Governor Maura Healey visited the MassBio headquarters in Cambridge, meeting with roughly 50 CEOs of early-stage biotech companies. The gathering, held on a Wednesday afternoon, was intended to discuss the challenges facing the sector ahead of the upcoming election.

Healey emphasized that access to capital has become a critical issue, noting that venture firms are increasingly favoring less risky investments. She also pointed to rising cost-of-living pressures that add to the financial strain on early-stage drug developers.

The governor asked how state programs could be better aligned to incentivize venture investment and support these companies, warning that many early-stage startups are at risk of failing without additional funding and policy assistance.